Allied Health & Imaging · Independent exam preparation
SOCRA CCRP®: Research Decisions, Ethics, and Regulatory Practice Study Guide
Practise consent, safety reporting, investigational product control, and closeout decisions with 60 focused concepts and original SOCRA CCRP study drills.
By CertMedbry · Updated 31 October 2026
Learn to distinguish approval requirements, protect voluntary participation, classify safety events, preserve reliable records, and close studies responsibly. These 60 selected concepts follow SOCRA's Research Study Start-Up, Research Study Implementation, and Research Study Closure domains in a 24/30/6 distribution. The 20 questions and 20 flashcards each use an 8/10/2 distribution. The official detailed examination outline defines the full scope; this selective guide supports study alongside that outline and the primary standards.
Try 20 free practice questionsWhat is the exam format?
Check the question types, timing and outline before planning your revision.
How many questions are on the examination, and which count toward the result?
The February 16, 2026 handbook specifies 130 questions: 100 scored and 30 unscored questions used to evaluate potential future items. Questions are equally weighted. Answer every question; the handbook does not provide a method for identifying the unscored questions.
Which question styles and delivery methods are verified?
The examination uses multiple-choice questions with four response options and one correct response. Most questions present scenarios requiring analysis and application. It is offered in English through computer-based testing at approved Prometric centers or through ProProctor with live remote proctoring. The handbook does not identify the examination as computer adaptive.
What is confirmed about examination duration and breaks?
SOCRA's [Exam Day Policies & Procedures](https://socra.org/certification/ccrp-certification-exam/exam-day-policies-procedures/) lists a four-hour examination allowance. That page also contains legacy paper-examination instructions, so candidates should follow their current appointment instructions and approved accommodations. The February 16, 2026 handbook permits a brief midpoint break after submitting questions 1–65. Submitted first-half questions cannot be revisited, and the examination clock continues during the break.
SOCRA — CCRP Certification Exam · SOCRA CCRP Candidate Handbook — 2026
Which blueprint and guideline version does this guide follow?
The current linked outline derives from the 2024 Job Task Analysis: Research Study Start-Up 40%, Research Study Implementation 50%, and Research Study Closure 10%. The handbook version date is February 16, 2026. SOCRA specifies ICH E6(R3) examination content beginning January 1, 2026. The standalone outline prints no separate effective date.
SOCRA — Exam Outline · SOCRA CCRP Candidate Handbook — 2026 · SOCRA — Scope and Standards of Practice
Do the eligibility categories lead to different examinations?
The handbook describes three eligibility categories combining qualifying clinical research experience with specified education where applicable. They lead to the same CCRP certification examination, rather than separate coordinator, monitor, or investigator examinations. This guide follows that common examination pathway.
How do jurisdiction and the historical CCRA name affect preparation?
SOCRA's examination scope includes ICH guidance, U.S. regulations, and research ethics, while practitioners must also follow applicable national and local requirements. U.S. regulatory examples in this guide identify their jurisdiction. SOCRA changed its designation from Certified Clinical Research Associate to Certified Clinical Research Professional in January 2000; that historical name does not identify a separate current SOCRA examination.
Is there a verified numerical passing score?
SOCRA's current Exam Outline publishes a passing requirement of 71 correct answers out of the 100 scored questions. The handbook explains that experts establish the cut score, psychometric analysis validates it, and equating supports comparability across examination forms. Scores from these learning questions should guide review of reasoning and knowledge gaps, rather than be interpreted as a predicted certification result.
The Certified Clinical Research Professional certification recognizes foundational knowledge and experience in human clinical research across job titles. It is awarded by the Society of Clinical Research Associates and is not a nursing license or specialty prescribing credential. These independently authored learning materials are not official SOCRA examination questions or a prediction of passing performance.
Outline used: SOCRA Candidate Handbook, version date February 16, 2026; current linked outline based on the 2024 Job Task Analysis: Research Study Start-Up 40%, Research Study Implementation 50%, Research Study Closure 10%. SOCRA specifies ICH E6(R3) examination content beginning January 1, 2026. Verified for October 12, 2026. The workbook label 'Certified Clinical Research Professional (CCRP - SoCRA)' maps to this official CCRP certification examination; 'SoCRA' identifies SOCRA, not a separate credential. Assigned slug preserved. The standalone outline does not state a separate effective date.
60 key concepts: understand, apply and avoid the traps
Work through the questions by exam domain. Explain the answer in your own words, try the example, then check the common pitfall.
Research Study Start-Up40%
1.How does respect for persons shape research participation?
Respect for persons combines recognition of autonomous decision-making with protection for people whose autonomy is diminished. A valid research decision therefore requires more than a signature: information must support understanding, and the person must have a meaningful opportunity to choose. The discriminating clue is whether the recruitment and consent process enables an independent decision, particularly when illness, dependency, or impaired capacity could limit that independence.
Apply it
A clinic supervisor invites employees into a study during performance reviews. Redesign recruitment so employees can consider participation privately, understand that employment is unaffected, and decline without reporting their decision to the supervisor.
Common pitfall: Treating a signed form as proof of autonomy overlooks pressure from authority relationships and the participant's actual opportunity to understand and refuse.
2.How does beneficence guide a risk–benefit assessment?
Beneficence requires efforts to avoid harm, minimize possible harms, and maximize possible benefits. Assess both the probability and magnitude of harm, the procedures creating it, and whether the scientific question justifies those procedures. Potential benefit does not erase avoidable risk. A useful decision cue is whether the same scientifically valid information could be obtained through a less burdensome or safer approach.
Apply it
A protocol proposes repeated research blood draws although a validated analysis needs fewer samples. Ask whether reducing collection preserves the study objective while lowering discomfort, blood loss, and visit burden for enrolled participants.
Common pitfall: Assuming an important research question justifies every proposed procedure confuses social value with the separate duty to eliminate unnecessary participant risk.
3.Which recruitment choices raise concerns about justice?
Justice concerns the fair distribution of research burdens and benefits. Selection should reflect the scientific question and relevant population, rather than simply targeting people who are easily available, dependent, or less able to resist. Fairness does not require identical enrollment from every group. The key distinction is between scientifically justified selection and convenient selection that places burdens on a group unlikely to share in resulting benefits.
Apply it
A team proposes recruiting only residents of a dependent-care facility because access is easy, although the intervention targets community adults broadly. Reassess whether that population is scientifically appropriate and whether recruitment distributes burdens fairly.
Common pitfall: Equal payment does not by itself establish justice when the population was selected primarily for convenience or vulnerability rather than scientific relevance.
4.How should objectives, endpoints, and procedures connect?
A study objective states the question to be answered; an endpoint specifies the measurement used to answer it. Procedures, timing, and analysis should support that relationship. An impressive volume of collected data cannot compensate for an endpoint that misses the intended question. During protocol development, ask whether the endpoint is clearly defined, measured consistently, and interpretable in relation to the stated objective and planned comparison.
Apply it
A study aims to assess sustained functional improvement but records only an immediate postprocedure satisfaction score. Recommend an endpoint and assessment schedule that actually measure function over the period relevant to the objective.
Common pitfall: Choosing the easiest measurement can produce complete data that answer a different question, weakening both scientific value and the justification for participant burden.
5.How does randomization reduce allocation bias?
Randomization assigns participants by chance, reducing the opportunity for treatment selection based on prognosis or investigator preference. Allocation concealment protects the upcoming assignment before enrollment; it prevents staff from steering particular participants toward a preferred group. Randomization supports comparability but does not guarantee identical baseline characteristics in every sample. The discriminating cue is whether assignments can be predicted or influenced before an eligible participant is irreversibly enrolled.
Apply it
A coordinator can see the next treatment assignment and delays enrolling a participant with severe disease. Replace the exposed sequence with controlled allocation access so enrollment decisions cannot be shaped by the upcoming assignment.
Common pitfall: Alternating treatments may look balanced but remains predictable, allowing selection decisions that undermine the protection provided by genuine random allocation and concealment.
6.Why does blinding protect outcome interpretation?
Blinding limits knowledge of treatment assignment among people whose expectations could influence care, reporting, assessment, or analysis. Its purpose differs from allocation concealment, which protects assignment before enrollment. The protocol should identify who remains blinded and how essential emergency information can be accessed. When full blinding is infeasible, independent blinded outcome assessment may still reduce measurement bias without pretending that participants or treating staff are unaware.
Apply it
Surgeons cannot be blinded to the operation performed. The team instead arranges standardized functional testing by assessors who do not know assignment, reducing the influence of treatment expectations on the primary outcome measurement.
Common pitfall: Calling a study blinded without identifying who is blinded hides important bias pathways; a blinded analyst does not automatically protect unblinded outcome assessment.
7.Why must eligibility criteria be operationally precise?
Eligibility criteria define the population in which the question can be answered while addressing relevant safety concerns. Operational definitions specify the required measurement, threshold, timing, and acceptable evidence. Ambiguous criteria invite inconsistent enrollment and can compromise both protection and interpretation. The useful clue is whether two trained staff members reviewing the same records would reach the same eligibility decision without inventing exceptions or substituting personal clinical preferences.
Apply it
A draft protocol requires 'adequate kidney function' without a test, threshold, or assessment window. Request an explicit criterion before activation so sites can evaluate candidates consistently and document the same evidence for each decision.
Common pitfall: Leaving an important threshold to site preference creates variable study populations and may expose participants to risks the protocol intended to prevent.
8.How does quality by design change study planning?
ICH E6(R3) emphasizes designing quality into the trial rather than relying entirely on detecting errors afterward. Identify factors critical to participant protection and reliable results, then build feasible procedures and proportionate controls around them. Complexity itself can create errors. A useful decision is whether each added assessment or control addresses a meaningful risk, and whether removing unnecessary complexity would make critical processes more dependable.
Apply it
A team adds several exploratory forms that delay time-sensitive safety reviews. Reassess their value, simplify collection where justified, and protect staff capacity for eligibility checks, consent, and prompt review of clinically important results.
Common pitfall: Equating quality with maximum paperwork can divert attention from critical risks; a large document set does not demonstrate that essential trial processes work.
9.Which alternatives must informed consent explain?
For U.S. FDA-regulated research, informed consent must disclose appropriate alternative procedures or courses of treatment, if any, that might be advantageous to the participant. This supports a meaningful choice between research and other options. Alternatives should be relevant to the person's situation and described without implying that research participation is required for care. The discriminating cue is whether a reasonable alternative exists that could affect the decision.
Apply it
A candidate can receive an established treatment outside the trial. Revise the consent discussion to explain that option and relevant differences, allowing the candidate to compare it with research participation before deciding freely.
Common pitfall: Describing only the study arms omits potentially advantageous care outside the trial and can make participation appear to be the person's only option.
10.What makes consent language improperly exculpatory?
Under 21 CFR 50.20, consent may not include language through which participants waive, or appear to waive, legal rights or release investigators, sponsors, institutions, or agents from liability for negligence. Distinguish a factual explanation of available compensation or treatment from a release of responsibility. Consent must also use understandable language and provide sufficient opportunity to consider participation without coercion or undue influence.
Apply it
A draft form says participants surrender any right to seek compensation for negligent injury. Remove that waiver and replace it with an accurate explanation of available injury treatment, compensation arrangements, and appropriate contacts.
Common pitfall: Explaining that compensation is unavailable is different from asking participants to waive legal rights; the latter remains prohibited even when prominently disclosed.
11.How is a child's capacity for assent determined?
For FDA-regulated pediatric research, the IRB determines whether children are capable of assent by considering age, maturity, and psychological state. Assent means affirmative agreement; silence or failure to resist is insufficient. Parental permission and assent serve different functions. The IRB may assess capacity for all children in the study or individually, and regulatory exceptions require specific justification rather than a blanket assumption that permission replaces assent.
Apply it
A developmentally mature child understands a simple explanation but declines participation. Review the IRB's assent requirements and applicable determinations rather than treating parental permission alone as automatic authority to enroll the unwilling child.
Common pitfall: Using a universal birthday cutoff ignores the IRB's required assessment of maturity and psychological state and may misclassify a particular child's capacity.
12.How should safeguards address impaired decision-making capacity?
Vulnerability requires safeguards matched to the actual source of impaired choice, such as limited comprehension, dependency, or fluctuating capacity. Assess the person's ability to understand the study and decide voluntarily, and establish an appropriate consent pathway before enrollment. A family relationship alone does not establish legal authority to provide permission. Emergency research exceptions are specialized pathways with distinct requirements, rather than general solutions for difficult or time-pressured consent.
Apply it
A confused adult arrives with a sibling willing to sign. Assess capacity, verify whether the sibling has applicable legal authority, and use the approved consent pathway before any research procedure that requires consent begins.
Common pitfall: Assuming any accompanying relative may authorize research confuses family involvement with legally valid representation and bypasses assessment of the participant's own decision-making ability.
13.What makes a record essential to trial evaluation?
Essential records allow evaluation of trial conduct and the reliability of results, including whether participant rights, safety, and well-being were protected. Their value comes from the evidence they preserve, not merely from placement in a binder. Plan ownership, location, version control, access, and retention before the trial starts. Records may be distributed across systems if their locations and relationships remain clear and accessible.
Apply it
A site's training evidence sits in a separate institutional platform. Record its location and establish authorized access and retention arrangements so monitors and inspectors can reconstruct staff qualifications without requiring duplicate paper copies everywhere.
Common pitfall: Assuming an unsigned template proves a completed activity mistakes a planned process for evidence that the required action actually occurred in the trial.
14.How should case report forms support the protocol?
Case report forms should capture protocol-required information in a structured, interpretable way, with clear definitions, units, timing, and permissible responses. Design should support reliable transfer from source records without introducing ambiguity. Collecting unnecessary data increases burden and opportunities for error. A practical test is whether each field serves a defined trial purpose and whether staff can distinguish an unavailable value from a measurement that was never required.
Apply it
A laboratory field accepts a number without identifying units. Add an explicit unit specification or controlled unit selection so results from different laboratories cannot be silently interpreted as equivalent values during review and analysis.
Common pitfall: Relying on staff to remember local conventions allows apparently complete forms to contain values that cannot be compared or interpreted consistently across sites.
15.Which financial disclosure form fits the investigator's information?
Under 21 CFR 54.4, applicants use Form FDA 3454 to certify specified financial circumstances, including the absence of covered arrangements where applicable, and Form FDA 3455 to disclose covered interests or arrangements. The applicant's submission depends on accurate investigator information. Disclosure does not automatically mean exclusion from research; it enables evaluation of potential bias and measures used to minimize it. Distinguish certification from affirmative disclosure.
Apply it
A clinical investigator reports a covered financial arrangement relevant to a marketing application. Route the information for disclosure on Form FDA 3455, including the required details and bias-minimization information, rather than certifying its absence.
Common pitfall: Selecting Form FDA 3454 simply because an investigator signed a financial questionnaire confuses the collection document with the applicant's required certification or disclosure.
16.Why are sponsor, ethics, and regulatory permissions separate?
Different permissions answer different questions. Sponsor authorization supports operational activation, IRB or IEC review addresses ethical acceptability and participant protection, and regulatory authorization addresses applicable legal requirements for investigation. One permission does not automatically satisfy the others. Before initiation, identify every applicable prerequisite and its scope. The discriminating cue is whether approval applies to this protocol version, site, consent materials, and investigational pathway rather than merely to the project generally.
Apply it
A sponsor ships study supplies before the site's IRB approval is issued. Keep the site inactive for enrollment until the required permissions and readiness conditions are satisfied; shipment itself does not establish ethical authorization.
Common pitfall: Treating a sponsor's activation email as universal approval overlooks independent ethics and regulatory obligations that remain applicable even when funding and supplies are ready.
17.When can an IRB use expedited review?
Under 21 CFR 56.110, expedited review may be used for eligible categories of research involving no more than minimal risk and for minor changes in previously approved research during the approved period. Expedited describes a review procedure, not permission to skip ethical review. Designated reviewers may exercise the IRB's authority except disapproval; a proposal requiring disapproval must be considered through the nonexpedited procedure.
Apply it
An investigator requests expedited review of a minor wording change to an approved consent form. Assess whether the change qualifies, rather than deciding from urgency alone; the designated reviewer cannot issue a disapproval through that process.
Common pitfall: A short recruitment deadline does not make a study eligible for expedited review, and expedited reviewers do not have authority to disapprove research.
18.Which IRB membership features support independent review?
FDA-regulated IRBs must have at least five members with varied backgrounds, including at least one primarily scientific member, one primarily nonscientific member, and one member unaffiliated with the institution and not an immediate family member of an affiliated person. Diversity supports competent review of scientific and community concerns. Under 21 CFR 56.107(e), a member with a conflicting interest may not participate in the initial or continuing review, including deliberation and voting, except to provide information requested by the IRB.
Apply it
An IRB member is also an investigator on the submitted trial. Limit the member's participation to providing information requested by the IRB, then have the member withdraw from deliberation and voting. Confirm that the remaining review satisfies applicable membership and quorum requirements.
Common pitfall: Abstaining from the vote is insufficient if a conflicted member still participates in deliberation. Disclosure does not remove the restriction on review participation.
19.When does a U.S. IND become effective?
Under 21 CFR 312.40, an IND generally becomes effective 30 days after FDA receives it, unless FDA places the investigation on clinical hold, or earlier if FDA notifies the sponsor that the investigation may begin. Receipt is the relevant starting point, not the sponsor's mailing date. An effective IND does not replace IRB review, informed consent, or other prerequisites for beginning the particular investigation.
Apply it
A sponsor counts 30 days from courier pickup, although FDA received the submission later. Recalculate using FDA receipt and verify hold status or earlier authorization before assessing whether the IND is effective for study initiation.
Common pitfall: The passage of 30 days does not authorize proceeding through a clinical hold, and IND effectiveness alone does not establish that a site may enroll.
21 CFR 312.40 — General requirements for investigational new drug use
20.What follows an IRB significant-risk device determination?
For a device investigation presented as nonsignificant risk, 21 CFR 812.66 requires the IRB to make its own risk determination. If it determines that the investigation involves a significant-risk device, it must notify the investigator and, where appropriate, the sponsor. The investigation may not begin until FDA has approved the IDE application. Sponsor labeling of the investigation as nonsignificant risk does not override that determination.
Apply it
A sponsor submits a device study as nonsignificant risk, but the reviewing IRB determines significant risk. Pause initiation and obtain the required FDA IDE approval rather than proceeding under the sponsor's original classification and abbreviated requirements.
Common pitfall: IRB approval alone does not replace FDA IDE approval after a significant-risk determination, and a sponsor's preferred classification does not settle the issue.
21.How should site feasibility assess genuine capacity?
Site feasibility should test whether qualified personnel, facilities, equipment, time, and access to an appropriate participant population can support the protocol. Reputation or projected enrollment alone is insufficient. Evaluate competing workload and the practical demands of critical procedures, including emergency arrangements and data access. The useful discriminating cue is whether the site can reliably deliver the required activities, rather than merely agreeing that the protocol is interesting.
Apply it
A site forecasts high enrollment but lacks weekend coverage for mandatory safety assessments. Resolve coverage and resource needs before selection or activation, because projected recruitment cannot compensate for an inability to perform required participant protection procedures.
Common pitfall: Choosing the highest enrollment estimate can conceal operational weaknesses that later produce missed assessments, protocol deviations, or unsafe delays in reviewing important results.
22.How does delegation preserve investigator responsibility?
An investigator may delegate trial activities to appropriately qualified people while retaining responsibility for oversight of the trial at the site. Delegation should match competence, training, and the nature of the activity, with clear responsibilities and suitable supervision. A delegation log documents assignments but does not create competence. The decisive question is whether the investigator has reasonable assurance that delegated work is performed correctly and participant protection remains effective.
Apply it
A newly hired assistant appears on the delegation log for eligibility review but has no relevant training. Restrict the assignment until qualifications and training are established, and arrange investigator oversight appropriate to the clinical decisions involved.
Common pitfall: A signature on the delegation log does not transfer the investigator's responsibility or make an unqualified person competent to perform a regulated trial activity.
23.Which controls make an electronic data system fit for use?
For closed systems subject to 21 CFR 11.10, controls include validation for intended performance, authorized access, protection and retrieval of records, and secure time-stamped audit trails for relevant changes. Controls must preserve the content and meaning of the records over their required life. Purchasing commercial software does not establish fitness for a particular trial; intended use, configuration, interfaces, and operational procedures determine what must be demonstrated.
Apply it
A site adopts a commercial database for primary outcomes. Before use, evaluate its configured calculations, role permissions, audit trail, record export, and retention arrangements against the intended trial functions rather than relying solely on the vendor's reputation.
Common pitfall: Password protection alone addresses only part of the problem; a system can restrict access while still calculating incorrectly or losing the history of changes.
24.How should a multinational trial plan applicable requirements?
A trial's compliance plan must identify the requirements applicable to its locations, products, participants, and data flows. ICH guidance provides a common framework but does not erase national, state, provincial, or institutional obligations. Assign responsibility for ethics submissions, regulatory permissions, privacy arrangements, and public registration where applicable. Registration promotes transparency, but it does not substitute for ethics review or authorization to conduct the investigation at a site.
Apply it
A sponsor assumes approval in one country permits immediate enrollment at a newly added foreign site. Map that site's applicable permissions, privacy requirements, and registration responsibilities before activation rather than extending the original authorization by assumption.
Common pitfall: A public trial listing demonstrates disclosure of study information; it does not establish that every participating site has satisfied its local authorization requirements.
FDA — E6(R3) Good Clinical Practice, September 2025 · SOCRA CCRP Candidate Handbook — 2026
Research Study Implementation50%
25.How should eligibility be verified before enrollment?
Eligibility verification applies the approved criteria to current, participant-specific evidence before the relevant enrollment or treatment decision. Check the required assessment window, units, source results, and investigator judgment where the protocol requires it. A plausible clinical impression cannot replace a mandatory criterion. The decisive cue is whether all required evidence supports eligibility at the specified time, rather than whether missing documentation could probably be obtained afterward.
Apply it
A candidate's qualifying laboratory result falls outside the protocol's screening window. Obtain a timely assessment and confirm eligibility before enrollment instead of using the old result because the participant appears clinically unchanged today.
Common pitfall: Enrolling first and checking later can expose an ineligible person and cannot be cured simply by obtaining a qualifying result after the required decision.
21 CFR 312.60 — General responsibilities of investigators · FDA — E6(R3) Good Clinical Practice, September 2025
26.When does new information require an ongoing consent discussion?
Consent is an ongoing process because information emerging during a trial can change a participant's willingness to continue. Significant new findings relevant to that decision must be communicated, using appropriate approved materials and documentation. The key distinction is between an administrative change and information that alters the person's understanding of risks, benefits, alternatives, or participation requirements. Updating a form without a meaningful discussion may leave the original decision inadequately informed.
Apply it
New findings identify an important risk relevant to participants already receiving treatment. Arrange the required communication and consent update so each person can reconsider continued participation, rather than limiting the revised information to future recruits.
Common pitfall: A participant's original signature does not authorize withholding later information that could materially affect willingness to remain in the study and accept its risks.
21 CFR 50.25 — Elements of informed consent · FDA — E6(R3) Good Clinical Practice, September 2025
27.How can staff assess understanding during consent?
Understanding is better assessed through discussion than by asking only whether someone has questions. Invite the person to explain the study purpose, major risks, voluntary nature, and alternatives in their own words; clarify misunderstandings without coaching a predetermined answer. Information must be understandable and time for consideration sufficient. The decision cue is whether the person grasps the research choice, rather than whether every sentence was read aloud.
Apply it
A candidate says the trial guarantees the best treatment. Pause consent, explain uncertainty and research allocation, and ask the candidate to describe the difference between joining the trial and choosing established care outside it.
Common pitfall: Repeatedly reading the same technical wording can preserve confusion; a completed reading exercise does not establish that the participant understood the essential research decision.
28.How should withdrawal from participation be handled?
Participants may discontinue participation without penalty or loss of benefits to which they are otherwise entitled. Clarify what the person wishes to stop, such as study treatment, visits, or further contact, because these choices can differ. Explain appropriate safety follow-up without pressuring continued research involvement. Document the decision accurately and discuss applicable handling of existing information; do not promise that withdrawal automatically erases data already collected.
Apply it
A participant stops study medication because travel is difficult but is willing to discuss adverse events by telephone. Clarify and document the permitted follow-up arrangements while honoring the decision to stop treatment and avoiding pressure.
Common pitfall: Treating withdrawal as an all-or-nothing event can override the participant's actual preferences and unnecessarily lose acceptable safety follow-up or impose unwanted continued contact.
21 CFR 50.25 — Elements of informed consent · FDA — E6(R3) Good Clinical Practice, September 2025
29.How can retention support adherence without undue influence?
Retention strategies should remove avoidable barriers while preserving the participant's freedom to discontinue. Clear visit instructions, reasonable scheduling, and discussion of practical obstacles can improve completion of critical assessments. Investigate missed visits rather than assuming unwillingness or noncompliance. The discriminating cue is whether support enables the person's chosen participation or instead pressures them to remain despite discomfort, changed preferences, or an emerging safety concern.
Apply it
A participant repeatedly misses morning visits because of caregiving duties. Explore a protocol-compatible appointment time and explain essential assessments, while making clear that the participant can decline further involvement without losing ordinary clinical care.
Common pitfall: Threatening loss of routine care may increase attendance but undermines voluntary participation and turns an operational retention problem into an ethical consent problem.
FDA — E6(R3) Good Clinical Practice, September 2025 · 21 CFR 50.20 — General requirements for informed consent
30.When may an approved protocol amendment be implemented?
Protocol changes generally require the applicable sponsor, IRB or IEC, and regulatory review or authorization before implementation. A sponsor's revised document alone does not show that a site may start using it. Confirm the approved version, effective implementation arrangements, staff training, and related consent changes. The immediate-hazard exception is narrow: it permits necessary protective action, rather than routine implementation of changes chosen for convenience or faster recruitment.
Apply it
A sponsor distributes an amendment broadening eligibility, but the site's IRB has not approved it. Continue applying the currently approved criteria until the required authorization and implementation steps for the revised criteria are complete.
Common pitfall: Training staff on an amendment does not substitute for required approval, and sponsor endorsement does not authorize a site to bypass independent ethics review.
21 CFR 312.66 — Assurance of IRB review · FDA — E6(R3) Good Clinical Practice, September 2025
31.When can an investigator act before IRB approval?
For U.S. IND research, 21 CFR 312.66 permits changes without prior IRB approval when necessary to eliminate apparent immediate hazards to human subjects. The investigator must promptly report changes and unanticipated problems involving risk. The exception depends on an immediate protective need, not general efficiency. Document the hazard, the action, and the reason prior approval could not be obtained, while completing required notifications and subsequent review.
Apply it
A required study procedure creates an apparent immediate danger for a participant. The investigator stops the procedure, provides necessary care, documents the protective deviation, and promptly reports through the required channels instead of waiting for a meeting.
Common pitfall: Calling a change safer in general does not establish an immediate hazard; planned improvements ordinarily still require prospective review and approval before implementation.
32.How should a site maintain continuing IRB oversight?
The investigator must assure initial and continuing IRB review as applicable and provide information needed for that oversight. Track approval status, required progress submissions, modifications, and risk information rather than treating initial approval as permanent. For IND investigations, progress reports are provided to the reviewing IRB at intervals appropriate to risk and at least annually. Submission of a report is not itself evidence that any required renewed approval has been granted.
Apply it
A coordinator uploads the annual progress report shortly before approval expires. Confirm the IRB's review outcome and current authorization rather than assuming the upload automatically extends approval for new enrollment and other ongoing research activities.
Common pitfall: A submission receipt confirms delivery of documents, not the IRB's approval decision; confusing the two can allow research to continue without required oversight.
21 CFR 312.66 — Assurance of IRB review · 21 CFR 312.64 — Investigator reports
33.How does HIPAA authorization differ from research consent, and when can authorization be waived?
Research consent addresses agreement to participate; HIPAA authorization permits specified uses and disclosures of protected health information by covered entities. For an authorization waiver, an IRB or Privacy Board must find that the use or disclosure poses no more than minimal privacy risk, the research could not practicably be conducted without the waiver, and it could not practicably be conducted without access to and use of the PHI. Minimal privacy risk requires an adequate plan to protect identifiers, destroy them at the earliest opportunity consistent with the research unless retention has a health or research justification or is required by law, and adequate written assurances against reuse or disclosure except as required by law, for authorized oversight, or for other research permitted by the Privacy Rule. Required waiver documentation identifies the approving board and approval date, states that all three criteria are satisfied, briefly describes the PHI determined necessary, states whether normal or expedited review was used, and bears the chair's or designated member's signature.
Apply it
A covered hospital proposes a retrospective study requiring identifiable records to link outcomes across visits. Establish why the research is impracticable both without the waiver and without the PHI, specify identifier safeguards and justified retention or timely destruction, obtain the required written assurances, and verify complete board-approved waiver documentation before disclosure.
Common pitfall: Protocol approval, minimal physical risk, and recruitment inconvenience do not establish a HIPAA waiver. The board must make all three findings, including the separate necessity of access to the PHI.
34.How should confidentiality controls limit access to participant information?
Confidentiality protects information after it has been entrusted to the research team. Use access controls, coded identifiers, secure transfer, and separation of identifying keys where appropriate to the data's sensitivity and intended use. Coding does not make information anonymous when a reidentification key exists. The practical question is which people need identifiable information for an authorized purpose, rather than whether everyone belongs to the same institution.
Apply it
A study analyst needs outcome measurements but has no need for names or contact details. Provide a coded analysis dataset and restrict access to the identifying key, preserving an authorized route for necessary participant follow-up.
Common pitfall: Sending the identification key with every coded dataset defeats the intended separation and exposes identities to recipients who need only the research measurements.
FDA — E6(R3) Good Clinical Practice, September 2025 · HHS — HIPAA and Research
35.What must investigational drug receipt records establish?
Under 21 CFR 312.62, investigators must maintain adequate records of investigational drug disposition, including dates, quantity, and use by subjects. Receipt records establish the starting inventory and connect supplies to their identity, shipment, and condition. Reconcile what actually arrived with accompanying documentation before making it available for use. A delivery signature alone does not demonstrate that the correct product and quantity entered controlled study inventory.
Apply it
A shipment document lists twelve kits, but staff count eleven. Record the actual receipt, investigate the discrepancy with the sponsor, and resolve inventory status before relying on the shipment total for subsequent dispensing reconciliation.
Common pitfall: Copying the shipping quantity into the accountability log conceals shortages and makes later discrepancies appear to be dispensing or participant-return errors instead of receipt errors.
21 CFR 312.62 — Investigator recordkeeping and record retention · FDA — E6(R3) Good Clinical Practice, September 2025
36.How should a storage excursion affect product availability?
Investigational products must be stored under the conditions specified for the trial. An excursion creates uncertainty about suitability; appearance alone cannot establish stability. Identify and segregate affected supplies, preserve temperature and duration information, and obtain a documented suitability or disposition decision from the responsible party. The key distinction is between a product that appears normal and one whose continued use is supported by relevant stability information.
Apply it
A refrigerator alarm reveals an overnight temperature excursion. Prevent dispensing of affected kits, preserve the temperature record, notify the responsible sponsor contact, and document the resulting suitability decision before returning any supplies to available inventory.
Common pitfall: Returning stock to the refrigerator does not reverse a possible stability problem, and a normal-looking container provides no reliable evidence that the contents remain suitable.
37.Who may receive investigational drug supplies from the investigator?
Under 21 CFR 312.61, an investigator administers an investigational drug only to subjects under the investigator's personal supervision or that of a responsible subinvestigator. The investigator may not supply it to an unauthorized person. Product access is therefore governed by the investigation and authorized clinical responsibility, rather than ordinary professional familiarity. Another clinician's interest or prescribing status does not independently authorize transfer from trial stock.
Apply it
A physician outside the study asks for spare investigational tablets for a patient. Decline transfer from trial inventory and direct the request through an appropriate authorized pathway, preserving accountability and the investigation's control of supplies.
Common pitfall: Professional licensure or a colleague's good intentions do not make the recipient authorized to obtain investigational supplies from the site's controlled trial inventory.
38.How can product reconciliation reveal adherence problems?
Reconciliation compares supplies received, dispensed, returned, used, and otherwise disposed of to identify unexplained differences. Participant returns and reports can suggest adherence patterns, but a pill count alone cannot prove ingestion. Investigate discrepancies using the available records and a nonjudgmental discussion. The useful distinction is between an accounting observation and a verified clinical conclusion; accurate records should preserve uncertainty rather than convert missing tablets into assumed doses.
Apply it
A participant returns fewer tablets than expected but reports several missed doses. Review dispensing dates, losses, diary entries, and the participant's explanation instead of calculating perfect adherence solely from the number of tablets absent.
Common pitfall: Treating every missing tablet as swallowed can overestimate exposure and distort interpretation of both treatment response and adverse events during the trial.
FDA — E6(R3) Good Clinical Practice, September 2025 · 21 CFR 312.62 — Investigator recordkeeping and record retention
39.When is emergency unblinding justified?
Emergency unblinding is justified when knowledge of assignment is needed for appropriate participant care or another protocol-defined protective reason. Follow an accessible procedure that permits timely clinical action while limiting unnecessary disclosure. A serious event does not automatically require unblinding if management is independent of assignment. The discriminating question is whether knowing treatment changes the immediate clinical decision, rather than whether staff are curious about causality.
Apply it
A participant develops an event for which emergency management differs by assigned product. Use the authorized unblinding procedure promptly, document the reason and disclosures, and preserve blinding for people whose work does not require that information.
Common pitfall: Automatically unblinding every adverse event can introduce avoidable bias; delaying necessary unblinding to protect the study can compromise appropriate care for the participant.
40.How does an adverse event differ from a suspected adverse reaction?
Under 21 CFR 312.32, an adverse event is an untoward medical occurrence associated with drug use, whether or not considered drug related. A suspected adverse reaction requires a reasonable possibility that the drug caused the event, meaning evidence suggests a causal relationship. Temporal sequence alone does not establish causality. Separate the observation that an event occurred from the assessment of whether available evidence supports a drug-related reaction.
Apply it
A participant develops influenza during treatment after household exposure. Record and assess the event as required, but evaluate causal evidence rather than automatically classifying every illness after dosing as a suspected reaction to the drug.
Common pitfall: Using 'adverse event' and 'adverse reaction' interchangeably erases the causality distinction and can distort which findings warrant particular sponsor safety reporting decisions.
41.How does seriousness differ from severity?
Severity describes intensity, while seriousness depends on specified outcomes or medical significance. Under 21 CFR 312.32, serious events include death, immediate life threat, inpatient hospitalization or its prolongation, significant disability or incapacity, and congenital anomaly or birth defect. Important medical events may also qualify through medical judgment. A severe symptom can be nonserious, while a relatively mild presentation can still meet a serious outcome criterion.
Apply it
A participant reports a moderate symptom that results in inpatient hospitalization. Classify seriousness using the hospitalization criterion and assess intensity separately, rather than deciding that 'moderate' intensity makes the event nonserious for safety reporting.
Common pitfall: Life-threatening means immediate risk of death as the event occurred, rather than an event that might have been fatal if it had become more severe.
42.When must an IND investigator report a serious adverse event?
Under 21 CFR 312.64, an investigator must immediately report any serious adverse event to the sponsor, whether or not considered drug related, including an assessment of whether there is a reasonable possibility of causation. Protocol-defined serious endpoints may follow the protocol's reporting arrangement unless evidence suggests causality. Do not wait for complete records or proven causation before the required initial report; obtain and provide relevant follow-up information.
Apply it
A participant is hospitalized, and discharge records are unavailable. Notify the sponsor immediately with known facts and the investigator's initial causality assessment, then follow up as information develops rather than postponing the initial safety report.
Common pitfall: Waiting to prove a relationship to the investigational drug applies the wrong threshold to the investigator's immediate sponsor reporting duty for serious adverse events.
43.How is unexpectedness determined for expedited IND safety reporting?
Under 21 CFR 312.32(a), an event or suspected reaction is unexpected if it is not listed in the investigator brochure or differs from the listed information in specificity or severity. If no brochure is required or available, compare it with the risk information in the general investigational plan or elsewhere in the current application, as amended. Listed hepatic enzyme elevation does not make observed hepatic necrosis expected. An effect anticipated from the drug class or pharmacology remains unexpected until specifically observed with the particular investigational drug and included in the reference information. For an individual case, expedited sponsor reporting generally requires a serious, unexpected suspected adverse reaction, including evidence suggesting causality. Report qualifying cases as soon as possible and within 15 calendar days after determining they qualify; unexpected fatal or life-threatening suspected reactions have a seven-calendar-day limit after initial receipt. Other qualifying findings, including aggregate evidence, also require evaluation.
Apply it
The brochure lists hepatic enzyme elevation, but a participant develops hepatic necrosis. Classify the more specific event as unexpected, assess seriousness and causal evidence separately, and determine the applicable reporting category. Anticipated liver toxicity from related drugs does not establish expectedness for this drug.
Common pitfall: A broad listed risk, a less severe listed reaction, or a known class effect does not automatically cover the observed event. Expectedness requires comparison with the particular drug's reference information at the observed specificity and severity.
44.How can an unanticipated problem occur without physical injury?
A trial problem can threaten participants or others without producing a medical symptom. For IND investigations, investigators must promptly report unanticipated problems involving risk to human subjects or others to the IRB. Loss of identifiable sensitive information can create privacy, social, or economic risks. Assess the nature and implications of the occurrence rather than using the absence of an adverse event as proof that ethics reporting is unnecessary.
Apply it
A study laptop containing identifiable sensitive participant information is lost. Activate the privacy response and assess required IRB and other reporting, even though no participant has experienced a physical injury or reported a clinical symptom.
Common pitfall: Restricting risk reporting to medical adverse events misses confidentiality failures and other research problems that can harm participants or others through nonphysical pathways.
45.How should a deviation lead to effective corrective action?
A deviation is a departure from the protocol or other applicable trial requirement. Assess its effect on participant protection and data reliability, document facts, and make required notifications. Correction addresses the immediate problem; corrective and preventive action addresses causes and recurrence. The key cue is whether the proposed response changes the process that produced the error, with a way to check effectiveness, rather than merely restating that staff must comply.
Apply it
Several visits miss the same time-sensitive assessment because scheduling software uses an outdated window. Correct the configuration, review affected records, retrain relevant staff, and check subsequent visits to verify that the scheduling defect no longer causes omissions.
Common pitfall: Retraining alone is weak when the underlying cause is a faulty system; repeated reminders leave the same conditions available to produce the next deviation.
46.How should suspected fabrication be handled?
Suspected fabrication threatens both participant protection and the credibility of trial results. Preserve relevant records and change histories, limit further risk, and escalate through appropriate oversight channels for a fair investigation. Distinguish an unexplained discrepancy from an established finding of misconduct. Corrections must remain traceable; quietly replacing questionable data can destroy evidence and conceal the extent of the problem, even when intended to improve the final dataset.
Apply it
A monitor finds repeated assessments documented when appointment records show participants were absent. Preserve the source records and audit history, notify responsible oversight personnel, and investigate systematically rather than asking staff to recreate plausible measurements retrospectively.
Common pitfall: Accusing a person before investigation is premature, but silently editing suspicious values is also inappropriate because it removes evidence needed to establish what happened.
47.What makes source documentation reconstructable?
Source records should allow a reviewer to understand what occurred, when it occurred, who recorded it, and the basis for trial decisions. They support eligibility, consent, exposure, outcomes, and safety assessments. A case report form is not automatically the source merely because it contains a value; the designated data origin matters. Record information accurately and promptly, preserving traceable corrections and distinguishing observed facts from later interpretation.
Apply it
A source note records a symptom but omits its onset and clinical assessment. Obtain an attributable clarification from the responsible clinician using available evidence, rather than having data-entry staff invent dates to satisfy required form fields.
Common pitfall: A polished case report form cannot compensate for missing evidence about how a critical observation or decision arose in the original clinical research record.
FDA — E6(R3) Good Clinical Practice, September 2025 · 21 CFR 312.62 — Investigator recordkeeping and record retention
48.How should a data query be resolved?
A data query identifies an inconsistency, omission, or uncertainty requiring evaluation against the source and the study's data definitions. Resolve it using evidence and authorized clarification, with an attributable explanation or correction where needed. The aim is accurate data, not agreement with a preferred value. A valid response may confirm that an unusual value is correct or explain that a measurement is unavailable rather than manufacturing completeness.
Apply it
A query flags an unusually high laboratory result. Compare the original report, units, and collection date; confirm the value if supported, or correct a documented transcription error while preserving the reason and history of the change.
Common pitfall: Changing a value merely to clear an edit check substitutes plausibility for evidence and can remove a real safety finding or clinically meaningful outlier.
49.Why must electronic changes preserve an audit trail?
For applicable closed systems, 21 CFR 11.10 requires secure, computer-generated, time-stamped audit trails that independently record relevant actions creating, modifying, or deleting electronic records. Changes must not obscure previously recorded information. The audit trail supports reconstruction and accountability, but its existence does not make every change appropriate. Review should focus on whether activity is authorized, explainable, and consistent with the underlying evidence and intended system use.
Apply it
A participant's endpoint value changes shortly before database review. Examine the audit trail and supporting source clarification to establish who changed it, when, and why, rather than accepting the final displayed value without its history.
Common pitfall: A generic shared account weakens attribution because a time-stamped change cannot reliably identify the individual responsible when multiple people use the same login.
50.When should training and delegation records be updated?
Training and delegation must reflect current responsibilities, protocol requirements, and staff competence throughout the trial. Reassess them when personnel change, procedures are amended, systems are introduced, or performance reveals a knowledge gap. Attendance evidence is useful but may not demonstrate ability to perform a critical task. The decision cue is whether the person can carry out the assigned activity correctly under the current requirements before independently performing it.
Apply it
An amendment introduces a new device assessment. Train the relevant staff, confirm their ability to perform the procedure, and update responsibilities before implementation rather than relying on their training for the prior version of the assessment.
Common pitfall: Updating the training log after an unfamiliar procedure has already been performed does not establish that the person was prepared when participant-facing work occurred.
51.How long must an investigator update financial information?
Under 21 CFR 312.64, investigators must provide sponsors sufficient accurate financial information for required certification or disclosure and promptly update changes during the investigation and for one year after its completion. Financial review is therefore not limited to startup paperwork. The relevant clue is a change in covered interests or arrangements, not whether the investigator has already submitted an initial form or the site has stopped enrolling.
Apply it
An investigator acquires a relevant financial interest several months after the investigation ends. If within the required update period, promptly notify the sponsor so certification or disclosure information can remain accurate for the applicable regulatory submission.
Common pitfall: Closing enrollment does not end the financial update obligation, and an unchanged signature date does not demonstrate that the underlying financial circumstances remained unchanged.
52.How should safety information reach the right stakeholders?
Communication plans should identify what information goes to the sponsor, IRB or IEC, investigators, regulatory authorities, and independent monitoring bodies, with applicable urgency and responsibilities. These recipients have different roles, so informing one does not necessarily satisfy another obligation. An independent data monitoring committee reviews accumulating information within its charter; it does not replace local clinical judgment or the investigator's immediate responsibility for an individual participant.
Apply it
A site reports a serious event to the sponsor and assumes the independent monitoring committee will notify everyone else. Check the communication plan and complete any separate IRB reporting and participant protection actions required of the investigator.
Common pitfall: A single safety email is not evidence that every responsible body received the information it needs or that all recipient-specific reporting obligations were satisfied.
FDA — E6(R3) Good Clinical Practice, September 2025 · 21 CFR 312.64 — Investigator reports · 21 CFR 312.66 — Assurance of IRB review
53.How does risk-based monitoring direct oversight effort?
Monitoring is a quality control tool used to assess trial conduct and data, with attention to participant protection and reliable results. A risk-based approach directs effort toward important, plausible problems rather than assuming every field deserves identical review. The monitoring strategy should reflect the trial's design and risks and respond to emerging findings. Reduced routine checking does not justify neglecting critical consent, eligibility, exposure, or safety processes.
Apply it
Central review identifies unusual consent dates at one site while low-risk administrative fields remain complete. Direct monitoring toward the consent process and supporting records, rather than spending equivalent effort rechecking routine fields at every otherwise stable site.
Common pitfall: Risk-based monitoring is not simply fewer visits; it requires a reasoned allocation of oversight to risks that matter for participants and dependable trial conclusions.
FDA — A Risk-Based Approach to Monitoring of Clinical Investigations Questions and Answers · FDA — E6(R3) Good Clinical Practice, September 2025
54.How should a site interpret FDA Form 483 observations?
FDA Form 483 communicates inspectional observations that, in the investigator's judgment, may indicate violations of applicable requirements. It does not constitute FDA's final determination that a violation occurred and may not be an all-inclusive list of concerns. Evaluate each observation, its scope and cause, participant or data impact, and the evidence supporting corrective action. A reasoned response should address the observed conditions rather than simply dispute the form's existence.
Apply it
An inspection identifies inconsistent drug accountability. Assess affected participants and inventory, determine the process failure, and document corrective measures and supporting evidence instead of treating the observation as either a final legal judgment or an optional suggestion.
Common pitfall: Because Form 483 is not a final agency determination, ignoring it is tempting but unsound; the observations still warrant prompt evaluation and an appropriate response.
Research Study Closure10%
55.What should a closeout review verify?
Closeout verifies that remaining participant, product, data, reporting, and record responsibilities are resolved or explicitly assigned. Review essential records for completeness and accessibility, outstanding findings, safety follow-up, product status, and archive arrangements. The last participant visit is a milestone, not proof that all obligations have ended. The decision cue is whether another responsible person can reconstruct the trial and carry out remaining duties after routine site activity stops.
Apply it
A site's final visit is complete, but a safety follow-up and several delegation records remain unresolved. Assign responsibility and document resolution plans before treating closeout as complete simply because enrollment and scheduled visits have ended.
Common pitfall: Using the final participant visit as the sole closure criterion overlooks administrative and safety obligations that can continue after participant-facing trial procedures have stopped.
FDA — E6(R3) Good Clinical Practice, September 2025 · SOCRA — Detailed CCRP Examination Content Outline
56.How should outstanding queries be handled before final data review?
Final data review should establish that important discrepancies and missing information have been investigated and accurately represented. Resolve outstanding queries against available evidence, document legitimate limitations, and verify that corrections are traceable. Database completion is not permission to invent values. After locking or finalizing data, subsequent changes require controlled procedures so the relationship between the analyzed dataset and its supporting records remains understandable and defensible.
Apply it
A closeout query asks for an assessment never performed. Confirm and document that it is missing, explain the relevant circumstances, and assess its impact rather than entering a normal value to make the dataset look complete.
Common pitfall: A dataset with no blank fields may be less trustworthy than one with documented missingness if apparent completeness was achieved through unsupported assumptions or retrospective invention.
57.How should unused investigational drug be reconciled at closure?
Under 21 CFR 312.62, when an investigation is terminated, suspended, discontinued, or completed, the investigator returns unused supplies to the sponsor or provides for their disposition under the applicable requirements. Reconcile receipts, dispensing, returns, and authorized disposition before closing accountability. Physical removal is not enough: records must establish what happened to the supplies. Discrepancies require investigation and documented resolution, rather than an unexplained adjustment to make totals balance.
Apply it
The final stock count differs from the accountability log by two kits. Investigate receipt, dispensing, return, and disposition records before return or authorized destruction, and preserve an accurate explanation of any discrepancy that cannot be resolved.
Common pitfall: Destroying supplies first can eliminate evidence needed to investigate a discrepancy, while changing the log total without support merely conceals the accounting problem.
21 CFR 312.62 — Investigator recordkeeping and record retention
58.Which final reports remain due after study completion?
For IND investigations, 21 CFR 312.64 requires an adequate investigator report to the sponsor shortly after participation is completed. Other closure communications depend on the applicable IRB, regulatory, sponsor, and public reporting requirements. These are separate obligations with different recipients and purposes. A closeout visit does not automatically file the reports. Assign responsibility, verify required content, and retain evidence of submission and any subsequent acknowledgment or action.
Apply it
A monitor completes the closeout visit, but no investigator final report has reached the sponsor. Prepare the required report and separately confirm applicable IRB closure and other reporting duties rather than assuming the visit satisfied them.
Common pitfall: Sending a closure notice to the IRB does not substitute for the investigator's sponsor report, because the recipients and information needs differ across reporting obligations.
21 CFR 312.64 — Investigator reports · SOCRA — Detailed CCRP Examination Content Outline
59.When does the U.S. IND investigator retention period end?
Under 21 CFR 312.62, investigator records are retained for two years after approval of a marketing application for the investigated indication. If no application is to be filed or it is not approved for that indication, retain records until two years after the investigation is discontinued and FDA is notified. The last visit does not start a universal two-year clock. Longer applicable legal, contractual, or institutional requirements may control.
Apply it
A site finished visits years ago, but the relevant marketing application was approved only recently. Calculate the regulatory period from the applicable approval milestone and check longer requirements before authorizing destruction of the investigator's study records.
Common pitfall: Counting two years from local closeout can authorize premature destruction because the regulation ties retention to specified application or discontinuation-and-notification milestones instead.
21 CFR 312.62 — Investigator recordkeeping and record retention
60.How can an archive remain usable throughout retention?
Archiving must preserve records, their meaning, and authorized access for the required retention period. Identify the custodian, storage location, access controls, retrieval process, and arrangements for readable electronic records and relevant metadata. Staff turnover or vendor contract expiration does not end record responsibilities. The discriminating test is whether needed records can actually be found, opened, understood, and produced, rather than whether a storage invoice or backup file exists.
Apply it
A study database vendor plans to close the site's account. Arrange verified exports, associated metadata and audit history, readable formats, and a responsible custodian before access ends, then confirm that archived records can be retrieved.
Common pitfall: Keeping an unreadable backup is not effective retention; preservation must include the practical ability to interpret and produce the records throughout their required life.
FDA — E6(R3) Good Clinical Practice, September 2025 · 21 CFR 11.10 — Controls for closed systems
What to focus on during revision
The following are CertMedbry study suggestions. Use the official outline to check the full scope of your examination.
- Use the official detailed outline to identify full-scope topics beyond these selected concepts, including emergency research, device-specific reporting, FDA forms, and applicable registration requirements.
- Spend approximately 40% of review time on startup decisions, 50% on implementation, and 10% on closure, then adjust for demonstrated weaknesses.
- Separate investigator duties from sponsor duties, especially immediate serious-event reporting versus expedited IND safety reporting.
- Distinguish consent from privacy authorization, severity from seriousness, allocation concealment from blinding, and correction from prevention.
- Study ICH E6(R3) principles alongside specifically identified U.S. regulatory requirements; do not assume a guideline replaces applicable law.
- Practise reconstructing decisions from source evidence, approval status, timestamps, product records, and traceable changes.
A practical preparation plan
1. Map the official scope
Mark each task in SOCRA's detailed outline as confident, uncertain, or unstudied. Use the current three domain names and 40/50/10 weights, and identify topics that require study beyond this selective guide.
2. Build a responsibility matrix
For consent, amendments, safety, product control, and closure, identify the responsible investigator, sponsor, IRB or IEC, and regulator. Add the triggering condition, required recipient, and timing only where the governing source establishes it.
3. Practise discriminating pairs
Explain the decisive difference in each frequently confused pair: serious versus severe, event versus suspected reaction, consent versus authorization, expedited review versus urgent review, and completed visits versus completed closeout.
4. Work the independent drills
Answer the 20 questions before reading explanations. For each error, state the overlooked cue and why the selected alternative fails. Review the relevant primary source rather than memorizing the option position.
5. Rehearse a complete study lifecycle
Walk one hypothetical trial from feasibility and approvals through enrollment, an emerging safety event, a data discrepancy, and closeout. Identify the evidence and communication needed at each decision, then use the flashcards for spaced recall.
Use your sample score as a starting point
The free set contains 20 original practice questions. It is a small learning sample, not an official examination or a validated pass prediction. Review each explanation and its source before moving to another topic.
Start the free sampleOfficial sources and updates
- SOCRA — CCRP Certification Exam
- SOCRA — Certified Clinical Research Professional Program Overview
- SOCRA CCRP Candidate Handbook — 2026
- SOCRA — Exam Outline
- SOCRA — Detailed CCRP Examination Content Outline
- SOCRA — Scope and Standards of Practice
- FDA — E6(R3) Good Clinical Practice, September 2025
- HHS OHRP — Read the Belmont Report
- 21 CFR 56.110 — Expedited review procedures
- 21 CFR 50.25 — Elements of informed consent
- 21 CFR 56.107 — IRB membership
- 21 CFR 312.40 — General requirements for investigational new drug use
- 21 CFR 812.66 — Significant risk device determinations
- 21 CFR 11.10 — Controls for closed systems
- 21 CFR 312.66 — Assurance of IRB review
- 21 CFR 312.64 — Investigator reports
- 21 CFR 312.32 — IND safety reporting
- 21 CFR 312.61 — Control of the investigational drug
- HHS — HIPAA and Research
- 21 CFR 312.60 — General responsibilities of investigators
- FDA — A Risk-Based Approach to Monitoring of Clinical Investigations Questions and Answers
- FDA — Form 483 Frequently Asked Questions
- 21 CFR 50.20 — General requirements for informed consent
- 21 CFR 312.62 — Investigator recordkeeping and record retention
- 21 CFR 50.55 — Parental permission and assent by children
- 21 CFR 54.4 — Certification and disclosure requirements
- download
- Federal Register :: Request Access
- Federal Register :: Request Access
Confirm current eligibility, fees, scheduling and policies directly with the examination provider. CertMedbry is independent and is not endorsed by these organisations. How we handle content and corrections.